BioCentury | Jul 16, 2018
Preclinical News

On-target mutations latest worry for CRISPR stocks

On the heels of preclinical studies evaluating off-target mutations driven by CRISPR-Cas9 gene editing, geneticist Allan Bradley’s group from the Wellcome Sanger Institute shifted the spotlight to on-target mutations that could result from the technology....
BioCentury | Mar 7, 2013
Distillery Therapeutics

Indication: Cancer

...week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Solid tumors Phosphatidylinositol glycan anchor biosynthesis class N (PIGN)...
...treat solid tumors. In 26 colorectal tumor samples and 20 cell lines showing chromosomal instability, PIGN...
...chromosomal instability and were frequently deleted in tumors. In a colorectal cancer cell line lacking PIGN...
Items per page:
1 - 2 of 2